Intensity Therapeutics lost $3.5 million last quarter and is starting to enroll patients in its clinical trials again.

Nov 5, 2026, 8:59 AM ETResultsRead the original at Benzinga

Bad for INTS

Intensity Therapeutics restarted enrollment in both studies, but broader site activation depends on new funding. Its $8.5 million cash balance and expected $1 million monthly burn point to funding pressure that outweighs the trial progress.

INTS · Intensity Therapeutics

AI read · Bad for INTS

The AI's read

The company has little room to expand enrollment without more money. Trial work and a new drug batch are adding to costs. Restarting both studies is encouraging, but it does not solve the cash need. Management is still looking for partners or other funding.

Get alerts for INTS

Follow Intensity Therapeutics (INTS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for INTS

Free on the App Store and Google Play, or on the web.